Result: The most prevalent of these mutations was V82F, detected in 5-8% of patients respectively in UK CHIC/HDRD and EuroSIDA.
Table: V82F
Discussion: Interestingly, mutation V82A was the first to be entered in our model leading to the largest decrease in ASE besides pre-TCE viral load while V82F which was more prevalent than V82A was not selected at all.
Decomposing the energetic impact of drug resistant mutations in HIV-1 protease on binding DRV.
PMID: 20543885
2010
Journal of chemical theory and computation
Discussion: Comparing the trajectories from MD simulations on the wild-type protease and the V82F/I84V protease variant, Perryman et al.
Design and synthesis of novel P2 substituents in diol-based HIV protease inhibitors.
PMID: 19926360
2010
European journal of medicinal chemistry
Abstract: These inhibitors were also tested against an HIV protease inhibitor resistant strain carrying the M46I, V82F, and I84V mutations.
HIV-1 protease mutations and protease inhibitor cross-resistance.
PMID: 20660676
2010
Antimicrobial agents and chemotherapy
Abstract: Of the mutations with the greatest effect on PI susceptibility, I84AV was associated with decreased susceptibility to eight PIs; V32I, G48V, I54ALMSTV, V82F, and L90M were associated with decreased susceptibility to six to seven PIs; I47A, G48M, I50V, L76V, V82ST, and N88S were associated with decreased susceptibility to four to five PIs; and D30N, PMID: 20587857
2010
Antiviral therapy
Abstract: Mutations V82A/F/T/S/M/I were primarily selected by the administration of ritonavir (RTV) in an historical ARV regimen.
Abstract: RESULTS: In protease (PR), resistance-associated mutations M46I/L, I54M/L/V/A/S and V82A/F/T/S/M/I were associated with each other and with minor mutations at codons 10, 24 and 71.
Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure.
PMID: 18992847
2009
Infection, genetics and evolution
Meth
Result: Ninety-seven percent of isolates with V82A/F/T/S mutations were from patients treated with IDV, RTV and/or LPV, and 89% of those with L90M were from patients treated with NFV and/or SQV.
Table: V82F
Discussion: The mutations L10F/R, K20I, V32I, I47V/A, I50L/V, I54L/A/M/T/S, A71T, G73C/T/A, V77I, and V82F/T/S, either absent or observed in our subtype B and F1 viruses, were not statistically different in viruses isolated from treated or untreated patients.
Revealing the drug resistance mechanism of saquinavir due to G48V and V82F mutations in subtype CRF01_AE HIV-1 protease: molecular dynamics simulation and binding free energy calculations.
PMID: 19219633
2009
Journal of computer-aided molecular design
Abstract: In this work, we have performed computer simulation of subtype AE HIV-1 PR with the drugs lopinavir (LPV) and nelfinavir (NFV), and examined the mechanism of resistance of the V82F mutation of this protease against LPV both structurally and energetically.
Abstract: The V82F mutation at the active site results in a conformational change of 79's loop region and displacement of LPV from its proper binding site, and these changes lead to rotation of the side-chains of residues D25 and I50'.
Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.
PMID: 19136678
2009
The Journal of antimicrobial chemotherapy
Abstract: Indinavir-associated mutations M46I/L, I84V and V82A/F/T developed earlier in subtype B across the time of exposure to that drug when compared with subtype G counterparts.
Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients.
HIV mutation literature information.
PMID: 
2011
Current HIV research
Browser Board
Co-occurred Entities
Filtrator
ViMRT